Viking Therapeutics' shares plunged after mixed phase 2 results for a GLP-1 candidate. However, the data wasn't nearly as bad ...

The investigational GLP-1 receptor agonist MET-097i, which may be able to be dosed just once a month, yielded weight loss of ...

In a further comparison using DPP-4i/SU as the reference, the GLP-1 RA/SGLT2i combination therapy had the greatest effect in ...

Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an ...

New data unveiled on Friday has Fractyl Health saying that Revita could be the first therapy to preserve weight loss after ...

New York City doctors reveals how weight-loss drugs reduce inflammatory cytokines by decreasing fat cells, potentially ...

GLP-1 RA Effects Beyond Glycaemic Control A RECENT network meta-analysis suggests that GLP-1 receptor agonists (GLP-1 RAs) ...

Pfizer's purchase of Metsera marks a significant step in enhancing its pipeline of GLP-1 medications. With Metsera’s investigational drugs, such as MET-097i and MET-233i, Pfizer is positioning itself ...

On September 26, 2025, Fractyl Health announced positive results from the REMAIN-1 Midpoint Cohort, showing that its Revita therapy helped maintain weight loss in patients who discontinued GLP-1 drugs ...

The GLP-1 market has grabbed considerable attention in the past couple of years, and there's little doubt as to which ...

India embraces GLP-1 medications as a major advance in diabetes and obesity care. Experts warn these drugs require medical ...